{"id":"W2793000264","doi":"10.1001/jamaoncol.2017.5808","title":"Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Active Biotech; Astellas Pharma; Eisai; Ipsen; Clovis Oncology; Advanced Accelerator Applications; Endocyte; Gilead Sciences; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Progression-free survival; Clinical endpoint; Clinical trial; Placebo; Discontinuation; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001573546,0.0002377677,0.000646412,0.000373122,0.0001293205,0.00004495775,0.0002254549,0.0001903393,0.00107926],"category_scores_gemma":[0.0008012327,0.0001695987,0.0001415308,0.0007142054,0.0006772188,0.0001496069,0.0001293854,0.0005333129,0.00007283432],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004802061,"about_ca_system_score_gemma":0.002134392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00107868,"about_ca_topic_score_gemma":0.004806214,"domain_scores_codex":[0.9970662,0.0004111493,0.0007183699,0.000542425,0.0006000032,0.0006618743],"domain_scores_gemma":[0.9980838,0.0004963676,0.0002220632,0.0004789762,0.0004061701,0.000312614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05395595,0.004528184,0.4186831,0.0006048815,0.001550223,0.00956274,0.01128526,0.000006428438,0.02626093,0.002692898,0.01723893,0.4536304],"study_design_scores_gemma":[0.08998401,0.05681799,0.6564928,0.001928121,0.0009979408,0.0006874314,0.005782302,0.0007936364,0.009656895,0.01691033,0.158721,0.001227503],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.952628,0.001943637,0.000008834462,0.02719903,0.0006067895,0.001815897,0.00006186935,0.00007711603,0.01565879],"genre_scores_gemma":[0.9919531,0.001398484,0.002790972,0.001049849,0.0004967361,0.0006364164,0.00006578599,0.00004234674,0.0015663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4524029,"threshold_uncertainty_score":0.9998339,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04999381704449428,"score_gpt":0.4252381961655681,"score_spread":0.3752443791210738,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}